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( ring C). X-ray crystallographic examinations [2, 8–10]
have demonstrated that the aminocoumarin moiety and
the substituted deoxysugar moiety are essential for the
binding of these compounds to the B subunit of gyrase.
The prenylated 4-hydroxybenzoate moiety ( ring A) of
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Eberhard-Karls-Universita¨t Tu¨bingen novobiocin and clorobiocin is important for the uptake
of these antibiotics by bacteria [8, 10] and contributesAuf der Morgenstelle 8
72076 Tu¨bingen weakly to the binding of the compounds to bacterial
gyrase [8–10]. Biosynthetically, the 3-dimethylallyl-2Institut fu¨r Pflanzenbiochemie
Weinberg 3 4-hydroxybenzoic acid moiety of clorobiocin and novo-
biocin is derived from 4-hydroxyphenylpyruvate and an06120 Halle (Saale)
Germany isoprenoid precursor [11–14].
Our group has cloned and sequenced the biosynthetic
gene clusters of clorobiocin (clo) [15], novobiocin (nov)
[16], and coumermycin A1 (cou) [17]. The aminocoumarinSummary
moiety (ring B) of all three substances is linked to the
acyl component (ring A) via amide bonds, and corre-The aminocoumarin antibiotics clorobiocin, novobio-
spondingly all three gene clusters contain an amide syn-cin, and coumermycin A1 are inhibitors of bacterial
thetase gene, i.e., cloL, novL, and couL, respectively.gyrase. Their chemical structures contain amide bonds,
The aim of the present study was the generation offormed between an aminocoumarin ring and an
new aminocoumarins by feeding of synthetic analogsaromatic acyl component, which is 3-dimethylallyl-
of the prenylated 4-hydroxybenzoate moiety ( ring A) to4-hydroxybenzoate in the case of novobiocin and
ring A defective mutants of the aminocoumarin antibioticclorobiocin. These amide bonds are formed under ca-
producers. To be incorporated into aminocoumarin anti-talysis of the gene products of cloL, novL, and couL,
biotics, these ring A analogs need first to be acceptedrespectively. We first examined the substrate specific-
by the amide synthetases of the producers, i.e., by CloL,ity of the purified amide synthetases CloL, NovL, and
NovL, and CouL, respectively. NovL was shown pre-CouL for the various analogs of the prenylated ben-
viously to activate the acyl component (ring A) by adenyl-zoate moiety. We then generated new aminocou-
ate formation and to transfer it onto the amino group ofmarin antibiotics by feeding synthetic analogs of the
the aminocoumarin ring without involvement of a3-dimethylallyl-4-hydroxybenzoate moiety to a mutant
4-phosphopantetheinyl cofactor [18]. In order to identifystrain defective in the biosynthesis of the prenylated
the most promising compounds as well as the mostbenzoate moiety. This resulted in the formation of 32
suitable organism for the feeding experiments, we over-new aminocoumarin compounds. The structures of
expressed and purified the three amide synthetases andthese compounds were elucidated using FAB-MS and
tested which ring A analogs were accepted by them.1H-NMR spectroscopy.
CloL was found to accept the most suitable range of
compounds, and therefore the clorobiocin producer was
Introduction chosen for subsequent mutasynthesis studies.
The aminocoumarin antibiotics clorobiocin, novobiocin,
and coumermycin A1 (Figure 1) are potent inhibitors of Results and Discussion
DNA gyrase produced by different Streptomyces sp.
strains [1–3]. Novobiocin (Albamycin, Pharmacia & Up- Overexpression and Purification of the Amide
john) has been licensed in the USA for the treatment of Synthetases CloL, NovL, and CouL
human infections with gram-positive bacteria such as For overexpression of the three amide synthetases in
Staphylococcus aureus and Staphylococcus epider- Escherichia coli (see Experimental Procedures), the
midis. Its efficacy has been demonstrated in preclinical genes novL, cloL, and couL were cloned into the expres-
and clinical trials [4–6]. However, due to their toxicity in sion vector pQE70, resulting in the plasmids pMS80 [18],
eukaryotes, their poor water solubility, and their low pUG018, and pMS90, respectively. The C-terminal His6-
activity against gram-negative bacteria, clinical use of tagged fusion proteins CloL, NovL, and CouL were puri-
these antibiotics remains restricted [2]. Therefore, it is fied by nickel affinity chromatography as described in
of interest to test whether new, structurally modified [18], yielding proteins of near homogeneity (Figure 2).
aminocoumarin antibiotics may overcome the limita- Purified NovL showed a specific activity of 14.5 nkat/
tions of the known compounds [1, 7]. mg protein and CloL 4.2 nkat/mg protein, both with
The characteristic structural moiety of the aminocou- 3-dimethylallyl-4-hydroxybenzoate (ring A) as substrate
marin antibiotics is a 3-amino-4,7-dihydroxycoumarin (1 nkat catalyzes a product formation of 1 nmol per
unit ( ring B) that is attached to the deoxysugar noviose second; product formation was assayed by HPLC). CouL
showed a specific activity of 7.4 nkat/mg protein using
its genuine acyl substrate 3-methylpyrrole-2,4-dicar-*Correspondence: heide@uni-tuebingen.de
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Figure 1. Structures of the Aminocoumarin
Antibiotics Clorobiocin, Novobiocin, and
Coumermycin A1
The acyl components involved in amide bond
formation are indicated by boxes.
boxylic acid ( 3-MePy-2,4-COOH) as substrate. All am- zoic acid (in RAA 200, 210, 220, and 300) increased the
reaction velocity of the CloL and NovL reactions. Inide synthetase activities were tested using the amino-
coumarin moiety (ring B) of novobiocin, ATP, and the contrast, a cyclohexyl substituent in the same position
(RAA 520) led to complete loss of activity. Compoundsrespective acyl component as substrates.
containing a hydroxy, keto, or ether function in the side
chain (RAA 530, 510, 230) were poor substrates. On theSubstrate Specificity of CloL, NovL, and CouL
other hand, compounds with an amide bond in the sideTo compare the substrate specificities of CloL, NovL,
chain were well accepted, especially by CloL, if theyand CouL for different acyl components, the genuine
contained a sufficiently large N-alkyl side chain (RAAsubstrates (ring A and 3-MePy-2,4-COOH) and 22 syn-
240, 250, and 260). 3-halogenated 4-hydroxybenzoicthetic ring A analogs (see Table 1 for structures) were
acids (RAA 270, 280) were accepted by all three amideused in the amide synthetase assay. Formation of the
synthetases. Interestingly, 3,5-dibromo-4-hydroxyben-resulting amides was observed by HPLC. Figure 3 shows
zoic acid (RAA 290) was very well accepted by CouLthe product formation expressed as relative activities in
but not by CloL and NovL. A similar observation wascomparison to the product formation with the respective
made for 3,5-dimethyl-4-hydroxybenzoic acid (RAAgenuine substrate.
200). Of the 4-aminobenzoic acid derivatives (RAA 560,Ring A ( 3-dimethylallyl-4-hydroxybenzoic acid) is
380, 570, and 390), only the 3-methyl compound RAAthe genuine substrate of CloL and NovL but was also
380 was accepted by CloL and CouL.very well accepted by CouL (Figure 3). In contrast,
The structure of all enzymatically formed amides3-MePy-2,4-COOH, the genuine substrate of CouL, was
shown in Figure 3 was confirmed by LC-MS- and LC-not accepted by CloL and NovL. 4-hydroxybenzoic acid
MS/MS experiments (see Experimental Procedures). Al-was accepted by the amide synthetases CloL and CouL
though the three amide synthetases CloL, NovL, andand to a lesser extent by NovL (see Figure 3). The pres-
CouL show 80%–86% identity on amino acid level andence of a linear alkyl side chain at C-3 of 4-hydroxyben-
differ only by two amino acids in size, they showed
marked differences in their substrate specificity. CloL
readily accepted many of the synthetic substrates. There-
fore, the clorobiocin producer (Streptomyces roseo-
chromogenes) was chosen for the subsequent feeding
experiments. This was also advantageous since cloro-
biocin has been shown to be an especially potent inhibi-
tor of DNA gyrase, six times more active than novobio-
cin [19].
Mutasynthesis Experiments: Feeding of Ring
Figure 2. Purification of the Amide Synthetases NovL, CloL, and A Analogs to a cloQ Mutant
CouL after Overexpression as a Fusion Protein with a C-terminal For production of novel aminocoumarin antibiotics by
His6 Tag in E. coli XL1 Blue MRF feeding of ring A analogs, we decided to use a mutant
SDS-PAGE was carried out as described in Experimental Proce- strain of the clorobiocin producer, defective in biosyn-
dures. Lanes 1, molecular weight (MW) marker; lanes 2, total protein
thesis of ring A. The gene cloQ, encoding a prenyltrans-before induction; lanes 3, total protein after IPTG induction; lanes
ferase essential for the biosynthesis of 3-dimethylallyl-4, soluble protein after IPTG induction; lanes 5, eluate from Ni2
affinity chromatography. 4-hydroxybenzoic acid (ring A) in S. roseochromogenes,
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Table 1. RAAs Used in This Study
Compound Name R1 R2 R3 Reference or Source
ring A OH H [27]
RAA 200 OH CH3 CH3 Lancaster
RAA 210 OH H [28]
RAA 220 OH H [28]
RAA 230 OH H [28]
RAA 240 OH H [28]
RAA 250 OH H [28]
RAA 260 OH H [28]
RAA 270 OH Cl H [28]
RAA 280 OH Br H [28]
RAA 290 OH Br Br Aldrich
RAA 300 OH H [28]
RAA 380 NH2 CH3 H Sigma
RAA 390 H H Fluka
RAA 500 OH H H Fluka
RAA 510 OH H [28]
RAA 520 OH H [28]
RAA 530 OH H [28]
RAA 540 OH H [28]
RAA 550 OH H [28]
RAA 560 NH2 H H Merck
RAA 570 NH2 NH2 H Fluka
RAA 580 CH3 NH2 H Fluka
was inactivated by in-frame deletion [14], and the re- isolated on a preparative scale using a Sephadex LH
20 column and HPLC. Their structures (Table 2) weresulting cloQ mutant was used for mutasynthesis expe-
riments. identified by negative-ion FAB-MS analysis and by
1H-NMR (see Experimental Procedures).Feeding experiments were performed with those ring
A analogs that had been accepted by CloL in vitro (with In each of the nine successful feeding experiments,
the expected direct clorobiocin analog could be iso-the exception of RAA 300, which was not available in
sufficient amount). In parallel control cultures, S. ro- lated, i.e., a compound that contained the externally
added ring A analog but was otherwise identical to cloro-seochromogenes wild-type produced 15 g/ml cloro-
biocin, while the cloQ mutant produced no clorobiocin. biocin in structure. All newly isolated compounds were
called novclobiocins, as in previous studies by our groupIn the feeding experiments, usually 10 mg of the respec-
tive ring A analog were added to 500 ml of the culture [20–22]. The isolated compounds were designated as
novclobiocins 211, 221, etc. (Table 2), corresponding tomedium of the cloQ mutant, 2 days after inoculation.
5–8 days later, the cultures were extracted and the cul- the numbering of the ring A analogs (Table 1). In addition
to these direct clorobiocin analogs, another series ofture extracts were analyzed by HPLC. In total, 13 differ-
ent ring A analogs were fed. Nine of these experiments compounds was isolated (designated novclobiocin 212,
222, etc.), which showed slightly longer retention timesled to the formation of new aminocoumarins, which were
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in HPLC. The 1H-NMR data showed that in these
“isoclorobiocins” the 5-methylpyrrole-2-carboxylic acid
was attached to the 2-OH instead of the 3-OH of the
deoxysugar. This was demonstrated by a shift of the
signal of the proton at C-2″ from 4.34 ppm in the cloro-
biocin derivative to 5.39 ppm in the isoclorobiocin deriv-
ative and of the signal of the proton at C-3″ from 5.71
ppm to 4.44 ppm. The molecular weight of the isocloro-
biocins was confirmed by FAB-MS. The natural occur-
rence of a similar isomer of novobiocin has been re-
ported previously [23], showing similar 1H-NMR data.
In five feeding experiments, compounds with slightly
shorter HPLC retention times than the direct clorobiocin
analogs were observed and identified as “descloro-
biocins.” FAB-MS analysis showed that their molecular
mass was 34 Da smaller than that of the parent com-
pound, consistent with the loss of a chlorine atom. While
the mass spectra of the clorobiocin and isoclorobiocin
compounds showed the typical isotopic pattern caused
by the chlorine isotopes 35Cl and 37Cl, the latter sub-
stances did not show this pattern, confirming the ab-
sence of chlorine. 1H-NMR data unequivocally proved
that the new substances carried a hydrogen instead of
a chlorine atom at C-8 of ring B. The signal at 7.20–7.29
ppm corresponding to H-6 of the clorobiocin derivative
was missing. Instead, a signal at 7.01–7.04 ppm for two
protons was observed as a broad singlet, which could
be assigned to H-6 and H-8. The coincidence of the
signals of H-6 and H-8 as a broad singlet has been
observed previously from a naturally occurring novobio-
cin derivative lacking the 8-methyl group [24]. These
new desclorobiocin derivatives were named novclobio-
cin 214, 233, 243, 253, and 383.
From two feeding experiments, compounds com-
pletely lacking the 5-methylpyrrole-2-carboxylic acid
moiety were isolated. This was obvious from their molec-
ular mass, reduced by 107 compared to the respective
clorobiocin derivative, and from the signals in the
1H-NMR spectra. These two substances were desig-
nated novclobiocin 213 and 283.
Feeding of 3-methyl-4-aminobenzoic acid (RAA 380)
resulted in similar clorobiocin, isoclorobiocin, and des-
clorobiocin derivatives, but also in two further com-
pounds. One of these substances lacked the chlorine
atom at position 8 of the aminocoumarin moiety and at
the same time carried the 5-methylpyrrole-2-carboxylic
acid at 2″-OH instead of 3″-OH, as could be deduced
from the 1H-NMR data. This compound was named nov-
clobiocin 384. The second compound contained both
the chlorine and the 3″-acyl group, but its 1H-NMR spec-
trum lacked the signal at 3.51 ppm. This showed the
absence of a O-methyl group at position 4 of the deoxy-
sugar. The molecular mass was confirmed by FAB-MS.
This substance was designated novclobiocin 385.
In several feeding experiments, aminocoumarin agly-
cons, i.e., compounds lacking the deoxysugar moiety,
could be found; their structures were confirmed by mass
Figure 3. Relative Activities of the Amide Synthetases NovL, CloL,
and CouL with Different Carboxylic Acids
Specific activities with the genuine substrates of the enzymes were
set as 100%.
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Table 2. Chemical Structures of the Novel Aminocoumarins Derived from Mutasynthesis Experiments
Compound Name R1 R2 R3 R4 R5
novobiocin CH3 H CONH2 CH3
clorobiocin Cl H Py CH3
novclobiocin 211 Cl H Py CH3
novclobiocin 212 Cl Py H CH3
novclobiocin 213 Cl H H CH3
novclobiocin 214 H H Py CH3
novclobiocic acid 215a Cl - - -
novclobiocic acid 216a H - - -
novclobiocin 221 Cl H Py CH3
novclobiocin 222 Cl Py H CH3
novclobiocic acid 223a Cl - - -
novclobiocic acid 224a H - - -
novclobiocin 231 Cl H Py CH3
novclobiocin 232 Cl Py H CH3
novclobiocin 233 H H Py CH3
novclobiocin 241 Cl H Py CH3
novclobiocin 242 Cl Py H CH3
novclobiocin 243 H H Py CH3
novclobiocin 251 Cl H Py CH3
novclobiocin 252 Cl Py H CH3
novclobiocin 253 H H Py CH3
novclobiocin 261 Cl H Py CH3
novclobiocin 262 Cl Py H CH3
novclobiocic acid 265a H - - -
novclobiocin 271 Cl H Py CH3
novclobiocin 272 Cl Py H CH3
novclobiocin 281 Cl H Py CH3
novclobiocin 282 Cl Py H CH3
novclobiocin 283 Cl H H CH3
novclobiocin 381 Cl H Py CH3
novclobiocin 382 Cl Py H CH3
novclobiocin 383 H H Py CH3
novclobiocin 384 H Py H CH3
novclobiocin 385 Cl H Py H
a The novclobiocic acids lack the entire deoxysugar moiety.
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Table 3. Negative Ion FAB Mass Spectral Data of the Isolated Aminocoumarins
Negative Ion FAB-MS (m/z)
Compound MW [M-H] [M-Ring C] Ring A Analog Ring B
novclobiocin 211 670 669/671 388 162 225
novclobiocin 212 670 669/671 n.d. 162 n.d.
novclobiocin 213 563 562 n.d. 162 n.d.
novclobiocin 214 636 635 354 162 191
novclobiocic acid 215 389 388/390 - 162 n.d.
novclobiocic acid 216 355 354 - 162 191
novclobiocin 221 668 667/669 386/388 n.d. 225
novclobiocin 222 668 667/669 386 n.d. 225
novclobiocic acid 223 387 386/388 - n.d. n.d.
novclobiocic acid 224 353 352 - n.d. n.d.
novclobiocin 231 700 699/701 418 n.d. 225
novclobiocin 232 700 699/701 418 n.d. 225
novclobiocin 233 666 665 384 192 191
novclobiocin 241 713 712/714 431/433 205 225
novclobiocin 242 713 712/714 431 205 225
novclobiocin 243 679 678 397 205 191
novclobiocin 251 727 726/728 445 n.d. 225
novclobiocin 252 727 726/728 445 219 225
novclobiocin 253 693 692 411 219 191
novclobiocin 261 741 740/742 459/461 233 225
novclobiocin 262 741 740/742 459 233 225
novclobiocic acid 265 426 425 - 233 191
novclobiocin 271 662 661/663/665 380 n.d. 225
novclobiocin 272 662 661/663/665 n.d. n.d. 225
novclobiocin 281 706 705/707/709 424 n.d. 225
novclobiocin 282 706 705/707/709 424 198 225
novclobiocin 283 599 598/600/602 n.d. 198 225
novclobiocin 381 641 640/642 359/361 n.d. 225
novclobiocin 382 641 640/642 359/361 n.d. 225
novclobiocin 383 607 606 325 n.d. 191
novclobiocin 384 607 606 325 n.d. 191
novclobiocin 385 627 n.d. n.d. n.d. n.d.
Symbols and abbreviations: x/y, two or more signals resulting from chlorine and/or bromine isotopes contained in the molecule; n.d., not
detectable.
spectrometric and 1H-NMR data. In analogy to novobio- ple, feeding of RAA 200, 390, and 510, which had been
poor substrates of CloL in vitro, did not result in thecic acid, a precursor of novobiocin, these compounds
were called novclobiocic acids, and their structures are formation of detectable amounts of new aminocoumarin
antibiotics. An exception was 4-hydroxybenzoate (RAAdescribed in Table 3.
In the nine successful mutasynthetic feeding experi- 500), which was well accepted in vitro but did not lead
to the formation of new aminocoumarins in vivo.ments, we could isolate on average 1.7 mg of pure cloro-
biocin derivative (range: 0.7–2.9 mg), 0.7 mg of pure In contrast, feeding of RAA 210, 220, 230, 240, 250,
260, 270, 280, and 380 resulted in the isolation of aisoclorobiocin derivative, and 0.1 mg of pure descloro-
biocin derivative after feeding of 10 mg of the respective total of 32 novel aminocoumarins. Compared to former
mutasynthetic experiments, e.g., by Ankenbauer et al.,ring A analog. There was a statistically significant cor-
relation between the in vitro conversion of the ring A who fed 13 different precursors and succeeded in the
isolation of 3 new compounds [25], and by Dutton etanalogs by CloL (Figure 3) and the total yield of new
aminocoumarins obtained in all 13 feeding experiments al., who fed 800 precursor substrates and succeeded
in the isolation of 36 new compounds [26], this is a very(correlation coefficient r 0.649; p 0.0164). For exam-
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bold letters represent the BglII site). The PCR mixture (100 l) con-successful outcome and demonstrates the usefulness
tained 100 ng of pCloLM template, 20 pmol of each primer, 0.2 mMof mutasynthetic approaches for the generation of new
dNTPs (Stratagene), Pfu DNA polymerase reaction buffer, 5% (v/v)aminocoumarin derivatives.
DMSO, and 3 units of cloned Pfu DNA polymerase (Stratagene). The
PCR product was digested with SphI and BglII before ligation into
Significance the same sites of the expression vector pQE70 (Qiagen), resulting
in a C-terminal in-frame fusion with the His6 tag of pQE70. The
resulting plasmid was designated as pUG018.This study describes the mutasynthetic generation,
pMS90 for overexpression of CouL was constructed in the sameisolation, and structure elucidation of novel aminocou-
way using primers couL-1 (5-TAGTCACTGCATGCCGAACAGGmarin antibiotics. In the past, mutasynthesis experi- GAC-3, bold letters represent the SphI site) and couL-2 (5-TGACT
ments often yielded only small amounts of com- CAGATCTCCTGTCCACCAG-3, bold letters represent the BglII site)
pounds, being of limited use for further evaluation. and was kindly provided by E. Schmutz from our group [29].
Therefore, the present study started with the overex-
Expression and Purification of the Amidepression of key biosynthetic enzymes, i.e., the amide
Synthetases NovL, CloL, and CouLsynthetases CloL, NovL, and CouL, from different
Escherichia coli XL1 Blue MRF (Stratagene, Heidelberg, Germany)strains and the investigation of their substrate speci-
was used as host for the expression of the amide synthetases NovL,
ficity in vitro. These experiments revealed CloL as a CloL, and CouL from the plasmids pMS80 [18], pMS90, and pUG018,
very promiscuous enzyme, which is why the clorobio- respectively. Expression and purification procedures using Ni-NTA-
cin producer was selected for mutasynthesis. agarose were carried out as described previously [18]. Protein con-
centrations were determined by the Bradford method [30] usingThe incorporation of various precursors by the re-
bovine serum albumin as a standard. SDS-PAGE was carried outcombinant amide synthetase CloL was compared in
according to the method of Laemmli [31], and protein bands werevitro and could then be recapitulated by in vivo feeding
stained with Coomassie Brilliant Blue R 250.
experiments. There was a statistically significant cor-
relation between the enzymatic in vitro conversion of Amide Synthetase Assay
precursor analogs by CloL and the subsequent yields The amide synthetase assay contained 1 mM ring A or ring A analog,
1 mM ring B of novobiocin (bearing a methyl group at C-8), 5 mMof new aminocoumarins obtained from feeding experi-
ATP, 5 mM MnCl2, 50 mM Tris-HCl (pH 8.0), and 0.5–2 g of thements in vivo. Therefore, in vitro investigations of the
respective protein in a final volume of 100 l. The reaction wassubstrate specificity of the respective enzymes may
carried out for 30 min at 30C and stopped by addition of 5 l 1.5
provide useful data to predict the success of subse- M trichloroacetic acid. The reaction mixture was extracted with ethyl
quent mutasynthetic experiments. acetate and analyzed using HPLC as described elsewhere [18].
Following this strategy, a whole set of pure, novel
aminocoumarins in often substantial quantities could Structure Elucidation of Enzymatic Products
The positive and negative ion electrospray (ES) mass spectra werebe obtained. The number of substances generated
obtained using a Finnigan MAT TSQ 7000 instrument (electrospraywas unusually high: feeding of the 13 substances that
voltage 4.5 kV, heated capillary temperature 220C, sheath and auxil-had been accepted by CloL in vitro to a mutant of the
lary gas: nitrogen) coupled with a Micro-Tech Ultra-Plus MicroLC
clorobiocin producer S. roseochromogenes resulted system equipped with a RP18-column (4 m, 1 100 mm, SepServ,
in the formation of 32 new aminocoumarin derivatives. Berlin). UV detection was at 305 nm. A gradient 10% to 90% MeOH
This sets the stage for the generation of further deriva- in 0.2% aqueous acetic acid was used; flow rate 70 l min1. Mass
spectra were averaged and background was subtracted. The colli-tives with improved pharmacological properties and
sion-induced dissociation (CID) spectra of the [M-H] and [MH]is an example of the powerful potential of mutasynth-
ions, respectively, during a HPLC run were recorded with a collisionesis to generate novel chemotypes of natural-product-
energy of 20 eV for positive ions as well as 25 eV for negative
derived antimicrobials. The present success in gener- ions, respectively; collision gas: argon, collision pressure: 1.8 103
ating new compounds may reinvigorate similar efforts Torr.
with other antimicrobial natural products. The key ions obtained by the CID spectra are listed in Table 4.
The negative ion CID spectra show the aminocoumarin moiety (m/z
206), and the positive ion ones show the complementary partExperimental Procedures
([M-206]).
Chemicals
Ring B and novobiocic acid were kindly provided by Pharmacia & Production and Analysis of New Aminocoumarins
Upjohn, Inc. (Kalamazoo, MI). Ring A was obtained by hydrolysis of from Mutasynthesis Experiments
novobiocin as described previously [27]. Commercially available ring Streptomyces roseochromogenes var. oscitans DS 12.976 was
A analogs (RAAs) were purchased from Aldrich, Fluka, Lancaster, kindly provided by Aventis and was routinely cultured in baffled
Merck, and Sigma. Additional substituted benzoic acids were syn- Erlenmeyer flasks containing a stainless steel spring. For the pro-
thesized as described by M.A. Dessoy [28]. The carboxylic acids duction of clorobiocin and novclobiocins, wild-type S. roseochro-
used in the amide synthetase assay are listed in Table 1. mogenes and the cloQ mutant defective in ring A biosynthesis [14]
were first precultured in YMG liquid medium containing 1% malt
extract, 0.4% yeast extract, 0.4% glucose (pH 7.3) at 30C and 180Construction of Plasmids pMS80, pUG018, and pMS90
for Expression of NovL, CloL, and CouL rpm for 2 to 3 days. Cells (1 ml culture) were then precultured in 50 ml
cornstarch medium (1% cornstarch (Becton-Dickinson, Heidelberg,as a C-Terminal His6-Tag Fusion Protein
pMS80 for overexpression of NovL has been described previ- Germany), 1% peptone (Roth, Karlsruhe, Germany), 0.5% meat ex-
tract (Merck, Darmstadt, Germany) (pH 7.0) for 2 days at 33C andously [18].
cloL was amplified by PCR using pCloLM (F. Pojer, personal com- 210 rpm. Five milliliters of this preculture was inoculated into 50
ml of production medium adapted from [32], prepared from 4.8%munication) as template. An SphI site was introduced at the place
of the natural start codon using primer cloL_P03f (5-TCACGCATG distillers’ solubles (Sigma-Aldrich, Deisenhofen, Germany), 3.7%
glucose, 0.0024% CoCl2  6 H2O (at this point, the pH of the mixtureCCGAACAAGGACCAC-3, bold letters represent the SphI site). At
the C terminus, a BglII site was introduced before the stop codon was adjusted to 7.8), 0.6% CaCO3, and 0.2% (NH4)2SO4. Two days
after inoculation of the production medium, 1 mg of ring A or of theusing primer cloL_P02r (5-CTCAGATCTCCTGTCCACCAGCAC-3,
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Table 4. Enzymatic Products Monitored by Full Scan CID Spectra
Key Ions in the Full Scan CID Spectra of the [M-H] and [MH]
Ions (m/z), Respectively
Compound MW [M-H] [206] [M-206]
novclobiocic acid 200 355 354  149
novclobiocic acid 210 369 368  163
novclobiocic acid 220 367 366  161
novclobiocic acid 230 399 398  193
novclobiocic acid 240 412 411  206
novclobiocic acid 250 426 425  220
novclobiocic acid 260 440 439  234
novclobiocic acid 270 361 360/362  155 (35Cl)
novclobiocic acid 280 406 404/406  199 (79Br)
novclobiocic acid 290 485 482/484/486  279 (79Br81Br)
novclobiocic acid 300 464 structure elucidation was performed previously [18]
novclobiocic acid 380 340 339 () 134
novclobiocic acid 390 354 353 n.d. 148
novclobiocic acid 500 327 326  121
novclobiocic acid 510 369 368  163
Symbols and abbreviations: , detectable; n.d., not detectable; x/y, two or more signals resulting from chlorine or bromine isotopes contained
in the molecule. For structures of R1, R2, and R3, see Table 1.
respective ring A analog dissolved in 200 l ethanol was added to 3. 1H-NMR spectra were measured on an AMX 400 spectrometer
(Bruker, Karlsruhe, Germany) using CD3OD as solvent.50 ml of culture medium of the cloQ mutant. Cultivation was carried
1H-NMR spectral data (400 MHz, CD3OD; br, broad) follow.out in 500 ml baffled flasks for 5 to 8 days at 33C and 210 rpm.
Novclobiocin 211For analytical purposes, 10 ml bacterial culture was acidified with
	 0.97 (t, J  7.6 Hz, 3H-9), 1.18 (s, 3H-6″), 1.35 (s, 3H-7″), 1.65HCl to pH 4 and extracted twice with an equal volume of ethyl
(sext., J  7.6 Hz, 2H-8), 2.29 (s, 3H-6), 2.62 (t, J  7.6 Hz, 2H-7),acetate. After evaporation of the solvent, the residue was redis-
3.51 (s, 3H-8″), 3.72 (d, J  10.3 Hz, H-4″), 4.34 (t, J  2.7 Hz, H-2″),solved in 0.5 ml methanol. After centrifugation, 100 l of the clear
5.71 (dd, J1  10.3 Hz, J2  2.7 Hz, H-3″), 5.72 (d, J  2.7 Hz, H-1″),supernatant was analyzed by HPLC with a Multosphere RP18-5
5.94 (d, J  3.5 Hz, H-4), 6.82 (d, J  8.4 Hz, H-5), 6.90 (d, J  3.5column (250  4 mm; 5 m; C&S Chromatographie Service, Du¨ren,
Hz, H-3), 7.29 (d, J  9.1 Hz, H-6), 7.72 (dd, J1  8.4 Hz, J2  2.2Germany) at a flow rate of 1 ml/min, using a linear gradient from
Hz, H-6), 7.78 (d, J  2.2 Hz, H-2), 7.89 (d, J  9.1 Hz, H-5).68% to 100% MeOH in 0.2% aqueous acetic acid in 37 min with
Novclobiocin 212detection at 340 nm. Authentic clorobiocin (Aventis) was used as
	 0.96 (t, J  7.4 Hz, 3H-9), 1.17 (s, 3H-6″), 1.37 (s, 3H-7″), 1.65standard.
(sext., J  7.4 Hz, 2H-8), 2.30 (s, 3H-6), 2.61 (t, J  7.4 Hz, 2H-7),For preparative isolation, cultivation was carried out in 500 ml
3.55 (d, J  9.7 Hz, H-4″), 3.64 (s, 3H-8″), 4.44 (dd, J1  9.7 Hz, J2 baffled flasks in 50 ml of medium as described above. Usually, a
3.1 Hz, H-3″), 5.39 (t, J  3.1 Hz, H-2″), 5.79 (d, J  3.1 Hz, H-1″),total of 500 ml bacterial culture was pooled, acidified with HCl to
5.95 (d, J  3.6 Hz, H-4),6.81 (d, J  8.4 Hz, H-5), 6.89 (d, J  3.6pH 4, and extracted with ethyl acetate after removing the lipophilic
Hz, H-3), 7.23 (d, J  8.9 Hz, H-6), 7.72 (dd, J1  8.4 Hz, J2  2.1components by treatment with petrol ether. The residue of the ethyl
Hz, H-6), 7.78 (d, J  2.1 Hz, H-2), 7.88 (d, J  8.9 Hz, H-5).acetate extract after evaporation of the solvent was dissolved in 3
Novclobiocin 213ml methanol and passed through a glass column (100  2.6 cm)
	 0.96 (t, J  7.5 Hz, 3H-9), 1.10 (s, 3H-6″), 1.30 (s, 3H-7″), 1.65filled with Sephadex LH 20 (Amersham Biosciences, Freiburg, Ger-
(sext., J  7.5 Hz, 2H-8), 2.62 (t, J  7.5 Hz, 2H-7), 3.40 (d, J  9.9
many) and eluted with methanol. The fractions after separation on
Hz, H-4″), 3.59 (s, 3H-8″), 4.11 (t, J  2.1 Hz, H-2″), 4.19 (dd, J1 Sephadex LH 20 were analyzed with HPLC using the conditions
9.9 Hz, J2  2.1 Hz, H-3″), 5.63 (d, J  2.1 Hz, H-1″), 6.80 (d, J mentioned above. Fractions containing novclobiocins were pooled
8.1 Hz, H-5), 7.22 (d, J  9.0 Hz, H-6), 7.72 (dd, J1  8.1 Hz,and further purified on a preparative HPLC column (Multosphere J2  2.0 Hz, H-6), 7.79 (d, J  2.0 Hz, H-2), 7.89 (d, J  9.0 Hz, H-5).120 RP18-5; 5 m; 250  20 mm, C&S Chromatographie Service, Novclobiocin 214
Du¨ren, Germany) using the same solvents and gradient as for the
	 0.97 (t, J  7.6 Hz, 3H-9), 1.20 (s, 3H-6″), 1.37 (s, 3H-7″), 1.66
analytical column but with a flow of 2.5 ml/min. The purified com- (sext., J  7.6 Hz, 2H-8), 2.29 (s, 3H-6), 2.63 (t, J  7.6 Hz, 2H-7),
pounds were subjected to 1H-NMR and MS analysis. 3.51 (s, 3H-8″), 3.68 (d, J  9.8 Hz, H-4″), 4.23 (br s, H-2″), 5.60 (dd,
J1  9.8 Hz, J2  3.5 Hz, H-3″), 5.70 (br s, H-1″), 5.94 (d, J  3.7 Hz,
Structure Elucidation and Characterization H-4), 6.82 (d, J  8.5 Hz, H-5), 6.90 (d, J  3.7 Hz, H-3), 7.04
The products were analyzed by 1H-NMR spectroscopy and by nega- (complex overlapping signal; J not determinable, H-6 and H-8),
tive ion FAB mass spectrometry. Negative fast atom bombardment 7.73 (d, J  8.5 Hz, H-6), 7.79 (br s, H-2), 7.92 (d, J  8.7 Hz, H-5).
(FAB) mass spectra were recorded on a TSQ70 spectrometer (Finni- Novclobiocic Acid 215
gan, Bremen, Germany) using diethanolamine as matrix. The mass 	 0.96 (t, J  7.3 Hz, 3H-9), 1.65 (q, J  7.3 Hz, 2H-8), 2.62 (t, J 
7.3 Hz, 2H-7), 6.80 (d, J  8.6 Hz, H-5), 6.85 (d, J  8.7 Hz, H-6),spectral data of the resulting novclobiocins are shown in Table
Clorobiocin Derivatives through Mutasynthesis
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7.71 (dd, J1  8.6 Hz, J2  2.3 Hz, H-6), 7.77 (d, J  8.7 Hz, H-5), (br s, H-2″), 5.79 (s, H-1″), 5.95 (d, J  3.5 Hz, H-4), 6.89 (d, J 
3.5 Hz, H-3), 6.93 (d, J  7.6 Hz, H-5), 7.23 (d, J  8.7 Hz, H-6),7.78 (br s, H-2).
Novclobiocic Acid 216 7.71 (d, J  7.6 Hz, H-6), 7.88 (d, J  8.7 Hz, H-5), 8.25 (br s, H-2).
Novclobiocin 243	 0.96 (t, J  7.4 Hz, 3H-9), 1.65 (sext., J  7.4 Hz, 2H-8), 2.62 (t,
J  7.4 Hz, 2H-7), 6.65 (d, J  1.3 Hz, H-8), 6.74 (dd, J1  8.7 Hz, 	 1.20 (s, 3H-6″), 1.23 (d, J  6.9 Hz, 3H-10 and 3H-11), 1.37 (s, 3H-
7″), 2.29 (s, 3H-6), 2.75 (sept., J  6.9 Hz, H-9), 3.51 (s, 3H-8″), 3.70J2  1.3 Hz, H-6), 6.81 (d, J  8.3 Hz, H-5), 7.72 (dd, J1  8.3 Hz,
J2  2.6 Hz, H-6), 7.78 (br s, H-2), 7.82 (d, J  8.7 Hz, H-5). (d, J  9.4 Hz, H-4″), 4.23 (br s, H-2″), 5.60 (dd, J1  9.4 Hz, J2 
3.0 Hz, H-3″), 5.62 (s, H-1″), 5.94 (d, J  3.6 Hz, H-4), 6.90 (d, J Novclobiocin 221
	 1.34 (s, 3H-7″), 2.29 (s, 3H-6), 3.39 (d, J  6.6 Hz, 2H-7), 3.51 (s, 3.6 Hz, H-3), 6.95 (d, J  8.3 Hz, H-5), 7.03 (complex overlapping
signal, J not determinable, H-6 and H-8), 7.72 (d, J  8.3 Hz, H-6),3H-8″), 3.71 (d, J  10.2 Hz, H-4″), 4.34 (br s, H-2″), 5.02 (dd, J1 
10.2 Hz, J2  1.8 Hz, H-9a trans), 5.06 (dd, J1  17.2 Hz, J2  1.8 7.92 (d, J  5.8 Hz, H-5), 8.32 (br s, H-2).
Novclobiocin 251Hz, H-9b cis), 5.70 (complex overlapping signal, J not determinable,
H-3″), 5.72 (d, J  3.6 Hz, H-1″), 5.94 (d, J  3.4 Hz, H-4), 6.02 (m, 	 1.19 (s, 3H-6″), 1.33 (s, 3H-10, 3H-11 and 3H-12), 1.33 (s, 3H-7″),
2.29 (s, 3H-6), 3.51 (s, 3H-8″), 3.71 (d, J  9.7 Hz, H-4″), 4.33 (s,H-8), 6.83 (d, J  8.4 Hz, H-5), 6.90 (d, J  3.4 Hz, H-3), 7.25 (d,
J  9.3 Hz, H-6), 7.75 (d, J  8.4 Hz, H-6), 7.78 (s, H-2), 1.18 (s, 1H-2″), 5.70 (br s, H-1″), 5.70 (complex overlapping signal, J not
determinable, H-3″), 5.94 (s, H-4), 6.90 (s, H-3), 6.94 (d, J  7.43H-6″), 7.88 (d, J  9.3 Hz, H-5).
Novclobiocin 222 Hz, H-5), 7.23 (d, J  8.5 Hz, H-6), 7.71 (d, J  7.4 Hz, H-6), 7.89
(d, J  8.5 Hz, H-5), 8.26 (s, H-2).	 1.18 (s, 3H-6″), 1.37 (s, 3H-7″), 2.30 (s, 3H-6), 3.39 (d, J  6.6 Hz,
2H-7), 3.55 (d, J  9.7 Hz, H-4″), 3.64 (s, 3H-8″), 4.44 (dd, J1  9.7 Novclobiocin 252
	 1.18 (s, 3H-6″), 1.32 (s, 3H-10, 3H-11 and 3H-12), 1.37 (s, 3H-7″),Hz, J2  2.8 Hz, H-3″), 5.01 (dd, J1  11.0 Hz, J2  1.3 Hz, H-9a
trans), 5.05 (dd, J1  16.8 Hz, J2  1.3 Hz, H-9b cis), 5.38 (t, J  2.8 2.29 (s, 3H-6), 3.56 (d, J  7.9 Hz, H-4″), 3.64 (s, 3H-8″), 4.44 (br
s, H-3″), 5.39 (s, H-2″), 5.78 (s, H-1″), 5.94 (br s, H-4), 6.88 (br s,Hz, H-2″), 5.78 (d, J  2.8 Hz, H-1″), 5.95 (d, J  3.3 Hz, H-4), 6.02
(m, H-8), 6.83 (d, J  8.0 Hz, H-5), 6.89 (d, J  3.3 Hz, H-3), 7.22 H-3), 6.94 (br s, H-5), 7.20 (br s, H-6), 7.70 (br s, H-6), 7.88 (br s,
H-5), 8.38 (br s, H-2).(d, J  8.6 Hz, H-6), 7.75 (d, J  8.0 Hz, H-6), 7.79 (s, H-2), 7.89 (d,
J  8.6 Hz, H-5). Novclobiocin 253
	 1.21 (s, 3H-6″), 1.33 (s, 3H-10, 3H-11 and 3H-12), 1.37 (s, 3H-7″),Novclobiocic Acid 223
	 3.39 (d, J  6.5 Hz, 2H-7), 5.02 (dd, J1  10.2 Hz, J2  1.7 Hz, 2.29 (s, 3H-6), 3.51 (s, 3H-8″), 3.70 (d, J  8.3 Hz, H-4″), 4.23 (s,
H-2″), 5.60 (complex overlapping signal, J not determinable, H-3″),H-9a trans), 5.06 (dd, J1  17.1 Hz, J2  1.7 Hz, H-9b cis), 6.02 (m,
H-8), 6.88 (d, J  8.7 Hz, H-6), 7.75 (complex overlapping signal, 5.61 (s, H-1″), 5.94 (d, J  5.0 Hz, H-4), 6.90 (d, J  5.0 Hz, H-3),
6.96 (d, J  5.1 Hz, H-5), 7.01 (complex overlapping signal, J notJ not determinable, H-6), 7.75 (complex overlapping signal, J not
determinable, H-5), 7.78 (s, H-2), 6.83 (d, J  8.3 Hz, H-5). determinable, H-6 and H-8), 7.72 (d, J  5.1 Hz, H-6), 7.92 (br s,
H-5), 8.38 (br s, H-2).Novclobiocic Acid 224
	 3.40 (d, J  6.5 Hz, 2H-7), 5.02 (dd, J1  10.4 Hz, J2  1.9 Hz, Novclobiocin 261
	 0.93 (t, J  6.6 Hz, 3H-13), 1.19 (s, 3H-6″), 1.35 (s, 3H-7″), 1.39H-9a trans), 5.06 (dd, J1  17.5 Hz, J2  1.9 Hz, H-9b cis), 6.02 (m,
H-8), 6.67 (d, J  1.9 Hz, H-8), 6.76 (dd, J1  9.1 Hz, J2  1.9 Hz, (complex overlapping signal, J not determinable, 2H-11 and 2H-12),
1.72 (m, 2H-10), 2.29 (s, 3H-6), 2.45 (t, J  6.6 Hz, 2H-9), 3.51 (s,H-6), 6.84 (d, J  8.4 Hz, H-5), 7.75 (d, J  8.4 Hz, H-6), 7.78 (s,
H-2), 7.81 (d, J  9.1 Hz, H-5). 3H-8″), 3.71 (d, J  5.5 Hz, H-4″), 4.34 (s, H-2″), 5.70 (complex
overlapping signal, J not determinable, H-1″), 5.70 (complex overlap-Novclobiocin 231
	 1.19 (s, 3H-6″), 1.20 (t, J  7.0 Hz, 3H-10), 1.35 (s, 3H-7″), 1.41 (d, ping signal, J not determinable, H-3″), 5.94 (d, J  3.6 Hz, H-4),
6.90 (d, J  3.6 Hz, H-3), 6.93 (d, J  8.4 Hz, H-5), 7.24 (d, J  7.9J  6.4 Hz, 3H-11), 2.29 (s, 3H-6), 3.45 (q, J  7.0 Hz, 2H-9), 3.51
(s, 3H-8″), 3.72 (d, J  9.3 Hz, H-4″), 4.34 (s, H-2″), 4.87 (obscured Hz, H-6), 7.71 (d, J  8.4 Hz, H-6), 7.89 (d, J  7.9 Hz, H-5), 8.21
(s, H-2).by water, H-7), 5.71 (dd, J1  9.3 Hz, J2  2.9 Hz, H-3″), 5.72 (s,
H-1″), 5.94 (d, J  3.5 Hz, H-4), 6.86 (d, J  8.5 Hz, H-5), 6.90 (d, Novclobiocin 262
	 0.93 (t, J  6.2 Hz, 3H-13), 1.18 (s, 3H-6″), 1.37 (complex overlap-J  3.5 Hz, H-3), 7.28 (d, J  8.8 Hz, H-6), 7.81 (d, J  8.5 Hz,
H-6), 7.90 (d, J  8.8 Hz, H-5), 7.98 (s, H-2). ping signal, J not determinable, 2H-11 and 2H-12), 1.37 (s, 3H-7″),
1.72 (m, 2H-10), 2.30 (s, 3H-6), 2.45 (t, J  7.2 Hz, 2H-9), 3.55 (d,Novclobiocin 232
	 1.18 (s, 3H-6″), 1.20 (t, J  6.9 Hz, 3H-10), 1.38 (s, 3H-7″), 1.41 (d, J  8.8 Hz, H-4″), 3.64 (s, 3H-8″), 4.44 (dd, J1  8.8 Hz, J2  3.3 Hz,
H-3″), 5.39 (s, H-2″), 5.79 (s, H-1″), 5.95 (d, J  3.5 Hz, H-4), 6.89J  6.4 Hz, 3H-11), 2.30 (s, 3H-6), 3.45 (q, J  6.9 Hz, 2H-9), 3.55
(d, J  9.7 Hz, H-4″), 3.64 (s, 3H-8″), 4.45 (dd, J1  9.7 Hz, J2  3.0 (d, J  3.5 Hz, H-3), 6.92 (d, J  7.9 Hz, H-5), 7.21 (d, J  9.1 Hz,
H-6), 7.72 (d, J  7.9 Hz, H-6), 7.88 (d, J  9.1 Hz, H-5), 8.24 (brHz, H-3″), 4.87 (obscured by water, H-7), 5.39 (t, J  3.0 Hz, H-2″),
5.79 (d, J  3.0 Hz, H-1″), 5.95 (d, J  3.6 Hz, H-4), 6.84 (d, J  s, H-2).
Novclobiocic Acid 2658.3 Hz, H-5), 6.89 (d, J  3.6 Hz, H-3), 7.23 (d, J  9.0 Hz, H-6),
7.80 (dd, J1  8.3 Hz, J2  3.5 Hz, H-6), 7.89 (d, J  9.0 Hz, H-5), 	 0.94 (t, J  6.8 Hz, 3H-13), 1.39 (complex overlapping signal, J
not determinable, 2H-11 and 2H-12), 1.72 (t, J  7.4 Hz, 2H-10),7.96 (d, J  3.5 Hz, H-2).
Novclobiocin 233 2.46 (t, J  7.4 Hz, 2H-9), 6.67 (d, J  1.8 Hz, H-1″), 6.77 (br d, J 
8.6 Hz, H-6), 6.95 (d, J  8.3 Hz, H-5), 7.71 (d, J  8.3 Hz, H-6),	 1.20 (t, J  6.7 Hz, 3H-10), 1.20 (s, 3H-6″), 1.37 (s, 3H-7″), 1.41 (d,
J  6.4 Hz, 3H-11), 2.29 (s, 3H-6), 3.45 (q, J  6.7 Hz, 2H-9), 3.51 7.81 (d, J  8.6 Hz, H-5), 8.29 (s, H-2).
Novclobiocin 271(s, 3H-8″), 3.68 (d, J 10.8 Hz, H-4″), 4.23 (br s, H-2″), 4.87 (obscured
by water, H-7), 5.59 (dd, J1  10.8 Hz, J2  3.1 Hz, H-3″), 5.61 (s, 	 1.18 (s, 3H-6″), 1.34 (s, 3H-7″), 2.29 (s, 3H-6), 3.51 (s, 3H-8″), 3.72
(d, J  10.0 Hz, H-4″), 4.35 (t, J  2.5 Hz, H-2″), 5.70 (dd, J1  10.0H-1″), 5.94 (d, J  3.6 Hz, H-4), 6.85 (d, J  8.1 Hz, H-5), 6.90 (d,
J  3.6 Hz, H-3), 7.01 (d, J  8.1 Hz, H-6 and 1H-8), 7.82 (d, J  Hz, J2  2.5 Hz, H-3″), 5.72 (d, J  2.5 Hz, H-1″), 5.94 (d, J  3.5
Hz, H-4), 6.90 (d, J  3.5 Hz, H-3), 6.96 (d, J  8.6 Hz, H-5), 7.258.1 Hz, H-6), 7.93 (d, J  8.1 Hz, H-5), 7.99 (br s, H-2).
Novclobiocin 241 (d, J  9.0 Hz, H-6), 7.81 (dd, J1  8.6 Hz, J2  1.8 Hz, H-6), 7.86
(d, J  9.0Hz, H-5), 8.02 (d, J  1.8 Hz, H-2).	 1.19 (s, 3H-6″), 1.23 (d, J  6.8 Hz, 3H-10 and 3H-11), 1.35 (s, 3H-
7″), 2.29 (s, 3H-6), 2.75 (sept., J  6.8 Hz, H-9), 3.51 (s, 3H-8″), 3.71 Novclobiocin 272
	 1.17 (s, 3H-6″), 1.38 (s, 3H-7″), 2.30 (s, 3H-6), 3.55 (d, J  9.7 Hz,(d, J  10.2 Hz, H-4″), 4.34 (s, H-2″), 5.71 (complex overlapping
signal, J not determinable, H-1″), 5.71 (complex overlapping signal, H-4″), 3.64 (s, 3H-8″), 4.44 (dd, J1  9.7 Hz, J2  2.6 Hz, H-3″), 5.39
(t, J  2.6 Hz, H-2″), 5.79 (d, J  2.6 Hz, H-1″), 5.95 (d, J  3.4 Hz,J not determinable, H-3″), 5.94 (d, J  3.5 Hz, H-4), 6.90 (d, J 
3.5 Hz, H-3), 6.93 (d, J  8.1 Hz, H-5), 7.24 (d, J  8.7 Hz, H-6), H-4), 6.89 (d, J  3.4 Hz, H-3), 6.97 (d, J  8.5 Hz, H-5), 7.24 (d,
J  8.9 Hz, H-6), 7.81 (dd, J1  8.5 Hz, J2  2.1 Hz, H-6), 7.88 (d,7.71 (d, J  8.1 Hz, H-6), 7.89 (d, J  8.7 Hz, H-5), 8.22 (s, H-2).
Novclobiocin 242 J  8.9Hz, H-5), 8.02 (d, J  2.1 Hz, H-2).
Novclobiocin 281	 1.18 (s, 3H-6″), 1.23 (d, J  6.8 Hz, 3H-10 and 3H-11), 1.38 (s, 3H-
7″), 2.30 (s, 3H-6), 2.75 (sept., J  6.8 Hz, H-9), 3.55 (d, J  9.7 Hz, 	 1.18 (s, 3H-6″), 1.35 (s, 3H-7″), 2.29 (s, 3H-6), 3.52 (s, 3H-8″), 3.72
(d, J  10.2 Hz, H-4″), 4.35 (t, J  2.4 Hz, H-2″), 5.70 (dd, J1  10.2H-4″), 3.64 (s, 3H-8″), 4.44 (dd, J1  9.7 Hz, J2  3.1 Hz, H-3″), 5.39
Chemistry & Biology
182
Hz, J2  2.4 Hz, H-3″), 5.73 (d, J  2.4 Hz, H-1″), 5.94 (d, J  3.6 mechanisms of drug inhibition of DNA gyrase. Bioessays 18,
661–671.Hz, H-4), 6.90 (d, J  3.6 Hz, H-3), 6.95 (d, J  8.0 Hz, H-5), 7.29
(d, J  9.0 Hz, H-6), 7.85 (dd, J1  8.0 Hz, J2  1.9 Hz, H-6), 7.87 4. Raad, I., Darouiche, R., Hachem, R., Sacilowski, M., and Bodey,
G.P. (1995). Antibiotics and prevention of microbial colonization(d, J  9.0Hz, H-5), 8.18 (d, J  1.9 Hz, H-2).
Novclobiocin 282 of catheters. Antimicrob. Agents Chemother. 39, 2397–2400.
5. Raad, I.I., Hachem, R.Y., Abi-Said, D., Rolston, K.V., Whimbey,	 1.17 (s, 3H-6″), 1.37 (s, 3H-7″), 2.30 (s, 3H-6), 3.55 (d, J  9.8 Hz,
H-4″), 3.64 (s, 3H-8″), 4.40 (s, H-2″), 4.44 (dd, J1  9.8 Hz, J2  3.3 E., Buzaid, A.C., and Legha, S. (1998). A prospective crossover
randomized trial of novobiocin and rifampin prophylaxis for theHz, H-3″), 5.79 (s, H-1″), 5.95 (d, J  3.5 Hz, H-4), 6.89 (d, J  3.5
Hz, H-3), 6.94 (d, J  8.6 Hz, H-5), 7.21 (d, J  9.0 Hz, H-6), 7.85 prevention of intravascular catheter infections in cancer pa-
tients treated with interleukin-2. Cancer 82, 403–411.(d, J  8.6 Hz, H-6), 7.87 (d, J  9.0Hz, H-5), 8.19 (br s, H-2).
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